My overwhelming impression after sitting through a day-long session titled “FDA Nanotechnology Public Meeting” was of the excruciatingly slow pace of the regulatory process, at least as it relates to nanotechnology in the US. In October, 2006, the FDA held an initial public meeting on this same topic. So what has changed between 2006 and 2008?

